ライフサイエンスコーパス: withdrawal syndrome

1 0% by minimal, moderate, and severe alcohol withdrawal syndrome).

2 ic opiates has been implicated in the opiate withdrawal syndrome.

3 , which contributes to genesis of the opioid withdrawal syndrome.

4 l and autonomic manifestations of the opiate withdrawal syndrome.

5 rrupting PD treatment might lead to a severe withdrawal syndrome.

6 havioral features associated with the opiate withdrawal syndrome.

7 e with more severe manifestations of alcohol withdrawal syndrome.

8 ealthcare system risk factors for iatrogenic withdrawal syndrome.

9 ns, which constitute a severe symptom of the withdrawal syndrome.

10 c effect of FKBP5 on the severity of alcohol withdrawal syndrome.

11 drawal symptoms in ICU patients with alcohol withdrawal syndrome.

12 ail during the first 2 weeks of the nicotine withdrawal syndrome.

13 ccounts for some but not all aspects of this withdrawal syndrome.

14 ich are likely to contribute to beta-blocker withdrawal syndrome.

15 amide and is likely involved in bicalutamide withdrawal syndrome.

16 ng the validity and significance of cannabis withdrawal syndrome.

17 l will lead to a better understanding of the withdrawal syndrome.

18 antigen, which might result in antiandrogen withdrawal syndrome.

19 ted by a less severe antagonist-precipitated withdrawal syndrome.

20 ible pathway that might contribute to the HF withdrawal syndrome.

21 especially for people who have experienced a withdrawal syndrome.

22 osure, and increased frequency of iatrogenic withdrawal syndrome.

23 AR) agonists that may result in antiandrogen withdrawal syndrome.

24 ctivity 24 h later, suggestive of a caffeine withdrawal syndrome.

25 ons, and are therefore at increased risk for withdrawal syndrome.

26 trexone, substance dependence, and substance withdrawal syndrome.

27 on, and treatment of neonatal and iatrogenic withdrawal syndromes.

28 fe-threatening complications, dependence and withdrawal syndromes.

29 s appear similar to those of other substance withdrawal syndromes.

30 ubation stridor, 22% vs. 53% (p < .001); and withdrawal syndromes, 0% vs. 43% (p < .001).

31 Subjects with iatrogenic withdrawal syndrome (544/1,157; 47%) were younger and mo

32 Chronic opioid-induced drug dependence and withdrawal syndrome after opioid cessation remain a seve

33 ng as criteria, adding cannabis and caffeine withdrawal syndromes, aligning tobacco use disorder crit

34 before weaning to better prevent iatrogenic withdrawal syndrome among at-risk patients.

35 ission has long been implicated in the acute withdrawal syndrome and as a key signal for dependence-r

36 rrence, predictors, and prognosis of alcohol withdrawal syndrome and delirium tremens in patients wit

37 Measures included occurrence of alcohol withdrawal syndrome and delirium tremens, injury charact

38 ity, validity, and time course of a cannabis withdrawal syndrome and have begun to explore the effect

39 Serious adverse events included the narcotic-withdrawal syndrome and sirolimus-associated pneumonitis

40 icant association between the development of withdrawal syndrome and the presence of ARDS (p = .017).

41 utcomes, pharmacologic treatment for alcohol withdrawal syndrome, and Clinical Institute Withdrawal A

42 sociated with congenital anomalies, neonatal withdrawal syndrome, and persistent pulmonary hypertensi

43 ed alcohol use leading to tolerance, alcohol withdrawal syndrome, and physical and psychological depe

44 Diagnostic criteria for cannabis withdrawal syndrome are proposed.

45 olism, models for specific factors, like the withdrawal syndrome, are useful for identifying potentia

46 Alcohol withdrawal syndrome assessment and its treatment options

47 A clinically important withdrawal syndrome associated with cannabis dependence

48 nergic agonist clonidine triggers a powerful withdrawal syndrome associated with massive CNS expressi

49 IE is validated as a model for human alcohol withdrawal syndrome (AWS) by demonstrating increased lev

50 Alcohol withdrawal syndrome (AWS) is a potentially fatal outcome

51 Alcohol withdrawal syndrome (AWS) symptoms include hyperexcitabi

52 ons into either brain region induced a quasi-withdrawal syndrome, but the observed behaviors differed

53 e of GHB or its analogs is associated with a withdrawal syndrome characterized by autonomic excitatio

54 ry characteristics, risk factors for alcohol withdrawal syndrome, clinical outcomes, pharmacologic tr

55 The association between ARDS and withdrawal syndrome, combined with the observation that

56 tate tumors may confer the development of HF withdrawal syndrome, commonly diagnosed in patients with

57 gth of stay, ICU length of stay, and alcohol withdrawal syndrome complications differed significantly

58 doses of opioids, several complications like withdrawal syndrome, delirium, mental status changes, an

59 Alcohol withdrawal syndrome developed in 0.88% (n = 246), includ

60 When nicotine is removed, a withdrawal syndrome develops.

61 d sedative medications are at risk for acute withdrawal syndromes during drug weaning.

62 Trauma patients with alcohol withdrawal syndrome experience a high occurrence of deli

63 pecific issues included possible addition of withdrawal syndromes for several substances, alignment o

64 physical dependence, shown by an attenuated withdrawal syndrome, from cocaine and U-50,488H.

65 Benzodiazepine withdrawal syndrome has also been associated with high d

66 ity and clinical significance of a marijuana withdrawal syndrome has not been established.

67 o possible that individual components of the withdrawal syndrome have individual and unique rate limi

68 n of opiate therapy can cause a debilitating withdrawal syndrome in chronic users.

69 We sought to identify a clonidine withdrawal syndrome in conscious rats by investigating t

70 dictive model of risk factors for iatrogenic withdrawal syndrome in critically ill children.

71 and screening tools associated with alcohol withdrawal syndrome in the ICU are reviewed.

72 ional or alternative strategies for managing withdrawal syndromes in ICU patients should therefore be

73 acologic strategies for treatment of alcohol withdrawal syndromes in the critically ill.

74 siology, diagnosis, and treatment of alcohol withdrawal syndromes in the intensive care unit as well

75 agnosis and treatment strategies for alcohol withdrawal syndromes in the intensive care unit.

76 alyses, significant predictors of iatrogenic withdrawal syndrome included younger age, preexisting co

77 of control over intake and the presence of a withdrawal syndrome, including both motivational and phy

78 f control over intake, and the presence of a withdrawal syndrome, including both motivational and phy

79 The intensity of the withdrawal syndrome indicates that chronic exposure to a

80 H (1 microM) displayed an abstinence-induced withdrawal syndrome, indicative of the development of ph

81 Iatrogenic withdrawal syndrome is common in children recovering fro

82 2-4-week period associated with the nicotine withdrawal syndrome is indicated when abstinence is atte

83 he hormone refractory stage to battle the HF withdrawal syndrome may become an alternative strategy t

84 aspirin is held preoperatively, the aspirin withdrawal syndrome may significantly increase the risk

85 Direct drug effects and withdrawal syndromes occurred in some neonates whose mot

86 Understanding the impact of cannabis withdrawal syndrome on quit attempts is of obvious impor

87 e (10 mg/kg) to induce naloxone-precipitated withdrawal syndrome on the final day of the experiment (

88 zodiazepines, results in the production of a withdrawal syndrome, one feature of which is increased s

89 The role of currently published alcohol withdrawal syndrome pharmacologic strategies (benzodiaze

90 Nine (32.1%) patients developed acute withdrawal syndrome potentially related to the administr

91 bstinence syndrome (NAS) is a postnatal drug withdrawal syndrome primarily caused by maternal opiate

92 Alcohol withdrawal syndrome progressed to delirium tremens in 11

93 ratory and clinical studies indicates that a withdrawal syndrome reliably follows discontinuation of

94 eline CIWA-Ar score, and established alcohol withdrawal syndrome risk factors.

95 In patients with severe alcohol withdrawal syndrome, severe head injury also predicted p

96 plications differed significantly by alcohol withdrawal syndrome severity and were worse with more se

97 ality also significantly differed by alcohol withdrawal syndrome severity but was only greater in pat

98 Before adjustment, alcohol withdrawal syndrome severity was associated with injury

99 Alcohol withdrawal syndrome severity was defined by CIWA-Ar scor

100 overdosed in the intensive care unit, though withdrawal syndromes should be prevented, and communicat

101 eously providing relief from the craving and withdrawal syndrome that accompanies cessation attempts.

102 ated prostate tumor growth, the antiandrogen withdrawal syndrome that allows antiandrogens to stimula

103 in chronic opiate abusers produces a severe withdrawal syndrome that is highly aversive, and avoidan

104 of the neonatal abstinence syndrome, a drug-withdrawal syndrome that most commonly occurs after in u

105 eported by patients given pregabalin, and no withdrawal syndrome was associated with pregabalin treat

106 Iatrogenic withdrawal syndrome was defined as having at least two W

107 The presence or absence of acute withdrawal syndrome was identified for each patient.

108 Nicotine withdrawal syndrome was precipitated by mecamylamine (2

109 ne receptor is relevant for the onset of the withdrawal syndrome, we used a mouse model of nicotine w

110 syndrome, combined with the observation that withdrawal syndromes were also associated with the use o

111 uscular blockers, pain assessments, and drug withdrawal syndromes were gathered during the first 28 d